UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 152

Sortiert nach

Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Rheumatology (Oxford, England), 2017-10, Vol.56 (10), p.kew431-1675

2017

Link zum Volltext

Verfügbarkeit prüfen

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity

Nature communications, 2020-12, Vol.11 (1), p.6149-6149, Article 6149

2020

Link zum Volltext

Verfügbarkeit prüfen

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus

Annals of the rheumatic diseases, 2017-11, Vol.76 (11), p.1829

2017

Link zum Volltext

Verfügbarkeit prüfen

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status

Annals of the rheumatic diseases, 2018-10, Vol.77 (10), p.1432

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil

Arthritis research & therapy, 2023-09, Vol.25 (1), p.1-160, Article 160

2023

Link zum Volltext

Verfügbarkeit prüfen

Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity

The Journal of immunology (1950), 2016-08, Vol.197 (4), p.1447-1459

2016

Link zum Volltext

Verfügbarkeit prüfen

Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Rheumatology (Oxford, England), 2017-10, Vol.56 (10), p.1662

2017

Link zum Volltext

Verfügbarkeit prüfen

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Arthritis research & therapy, 2017-10, Vol.19 (1), p.239-13, Article 239

2017

Link zum Volltext

Verfügbarkeit prüfen

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

Frontiers in immunology, 2022-01, Vol.12, p.803175-803175

2022

Link zum Volltext

Verfügbarkeit prüfen

Investigation of type I interferon responses in ANCA-associated vasculitis

Scientific reports, 2021-04, Vol.11 (1), p.8272-8272, Article 8272

2021

Link zum Volltext

Verfügbarkeit prüfen

An immunological biomarker to predict MTX response in early RA

Annals of the rheumatic diseases, 2014-11, Vol.73 (11), p.2047-2053

2014

Link zum Volltext

Verfügbarkeit prüfen

A glimpse into the future of systemic lupus erythematosus

Therapeutic Advances in Musculoskeletal Disease, 2022-03, Vol.14, p.1759720X221086719-1759720X221086719

2022

Link zum Volltext

Verfügbarkeit prüfen

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers

British journal of dermatology (1951), 2023-07, Vol.189 (2), p.210-218

2023

Link zum Volltext

Verfügbarkeit prüfen

Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity

Frontiers in immunology, 2020-06, Vol.11, p.1336-1336

2020

Link zum Volltext

Verfügbarkeit prüfen

Musculoskeletal manifestations of systemic lupus erythematosus

Best practice & research. Clinical rheumatology, 2023-12, Vol.37 (4), p.101859, Article 101859

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre

Rheumatology (Oxford, England), 2017-08, Vol.56 (8), p.1348-1357

2017

Link zum Volltext

Verfügbarkeit prüfen

Keratinocytes: From passive targets to active mediators of systemic autoimmunity

Science translational medicine, 2022-04, Vol.14 (642), p.eabo3961

2022

Link zum Volltext

Verfügbarkeit prüfen

Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective

Journal of investigative dermatology, 2022-03, Vol.142 (3), p.944-950

2022

Link zum Volltext

Verfügbarkeit prüfen

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Frontiers in medicine, 2020-08, Vol.7, p.498-498

2020

Link zum Volltext

Verfügbarkeit prüfen

A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus

Rheumatology (Oxford, England), 2024-01, Vol.63 (7), p.1837-1849

2024

Link zum Volltext

Verfügbarkeit prüfen

Musculoskeletal manifestations of systemic lupus erythmatosus

Current opinion in rheumatology, 2017-09, Vol.29 (5), p.486-492

2017

Link zum Volltext

Verfügbarkeit prüfen

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation

The Journal of immunology (1950), 2021-02, Vol.206 (4), p.785-796

2021

Link zum Volltext

Verfügbarkeit prüfen

Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus

The New England journal of medicine, 2022-10, Vol.387 (16), p.1528-1529

2022

Link zum Volltext

Verfügbarkeit prüfen

More to B: the growing evidence to inform targeting B cells in scleroderma

Rheumatology (Oxford, England), 2023-05, Vol.62 (5), p.1730-1732

2023

Link zum Volltext

Verfügbarkeit prüfen

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

ACR open rheumatology, 2022-08, Vol.4 (8), p.689-699

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(136)

Publikationsform

Sprache

Englisch
(152)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(90)
Humans
(73)
Rheumatology
(67)
Systemic Lupus Erythematosus
(34)
Female
(30)
Rituximab
(30)
Rheumatoid Arthritis
(28)
Lupus
(27)
Male
(26)
Arthritis, Rheumatoid - Drug Therapy
(24)
Middle Aged
(24)
Adult
(23)
Treatment Outcome
(21)
Antirheumatic Agents - Therapeutic Use
(19)
Lupus Erythematosus, Systemic - Drug Therapy
(16)
Biomarkers
(14)
Aged
(13)
Arthritis
(13)
Autoimmune Diseases
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status

Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil

Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity

Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

Investigation of type I interferon responses in ANCA-associated vasculitis

An immunological biomarker to predict MTX response in early RA

A glimpse into the future of systemic lupus erythematosus

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers

Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity

Musculoskeletal manifestations of systemic lupus erythematosus

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre

Keratinocytes: From passive targets to active mediators of systemic autoimmunity

Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus

Musculoskeletal manifestations of systemic lupus erythmatosus

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation

Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus

More to B: the growing evidence to inform targeting B cells in scleroderma

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

Suchergebnisse filtern